To the Editor: Bruton tyrosine kinase (BTK) inhibitor is now the standard of care for both treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Zanubrutinib, a next-generation BTK inhibitor with better BTK specificity and less offtarget inhibition, has demonstrated superior efficacy and improved safety profile compared with first-generation BTK inhibitor ibrutinib in large phase III ALPINE study.1 Zanubrutinib is the first next-generation BTK inhibitor approved in China for CLL/SLL in June 2020, and so far, the real-world data of zanubrutinib have not been reported. Thus, we present this multicenter real-world study detailing the efficacy and safety profile of zanubrutinib monotherapy in Chinese patients with CLL/SLL.
基金：
National Key R&D Program
of China (2023YFC2508900), the Innovation Program of Shanghai
Science and Technology Committee (23141903000) and the Innovative
Research Team of High-level Local Universities in Shanghai.
第一作者机构：[1]Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Hematol, Natl Res Ctr Translat Med Shanghai,Sch Med,State K, Shanghai 200025, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Luo Jing,Zhang Jiaojiao,Liu Ligen,et al.Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real-world study in China[J].AMERICAN JOURNAL OF HEMATOLOGY.2025,100(1):172-175.doi:10.1002/ajh.27519.
APA：
Luo, Jing,Zhang, Jiaojiao,Liu, Ligen,Wei, Rong,Yao, Yonghua...&Mi, Jian-Qing.(2025).Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real-world study in China.AMERICAN JOURNAL OF HEMATOLOGY,100,(1)
MLA：
Luo, Jing,et al."Efficacy and safety of zanubrutinib monotherapy for chronic lymphocytic leukemia/small lymphocytic lymphoma: A multicenter, real-world study in China".AMERICAN JOURNAL OF HEMATOLOGY 100..1(2025):172-175
医学